Key result
High glucose and high fat treatment induced ferroptosis in tendon-derived stem cells, and ferroptosis inhibition with ferrostatin-1 alleviated severe tendon injury in diabetic db/db mice.
Why the study?
Diabetes mellitus is a risk factor for tendinopathy, but the mechanism causing tendinopathy in patients with diabetes mellitus remains unclear.
Does ferroptosis inhibition with ferrostatin-1 alleviate tendinopathy in a diabetic mouse model?
Does ferroptosis inhibition with ferrostatin-1 alleviate tendinopathy in a diabetic mouse model?
Ferroptosis plays a key role in diabetic tendinopathy, and its inhibition may offer a novel therapeutic strategy.
No immediate practice change for diabetic tendinopathy; hypothesis-generating for ferroptosis-targeted therapies.
Tendinopathy is a condition characterized by chronic, complex, and multidimensional pathological changes in the tendons. The etiology of tendinopathy is the combination of several factors, and diabetes mellitus (DM) is a risk factor. Increasing evidence has shown that the diabetic microenvironment plays an important role in tendinopathy. However, the mechanism causing tendinopathy in patients with DM remains unclear. Our study found that ferroptosis played an important role in tendinopathy in patients with DM. In vitro, high glucose and high fat treatment was used to simulate the DM microenvironment. Results showed that such a mechanism significantly increased ferroptosis, which was characterized by mass cell death, lipid peroxide accumulation, mitochondrial morphological changes, mitochondrial membrane potential decline, iron overload, and the activation of ferroptosis-related genes, in tendon-derived stem cells cultured in vitro. In the animal studies, db/db mice were used in the DM model, and the db mice had severe tendon injury and high ACSL4 and TfR1 expressions. These phenomena could be alleviated by the ferroptosis inhibitor ferrostatin-1. In conclusion, ferroptosis is associated with tendinopathy in patients with DM, and ferroptosis targeting may be a novel approach for treating diabetic tendinopathy. Our results can provide a new strategy for managing tendinopathy clinically in patients with DM.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2023) studied Diabetic tendinopathy. High glucose and high fat treatment / Ferrostatin-1 was evaluated on Ferroptosis markers and tendon injury. High glucose and high fat treatment induced ferroptosis in tendon-derived stem cells, and ferroptosis inhibition with ferrostatin-1 alleviated severe tendon injury in diabetic db/db mice.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: